Verifying…
Home / Drug A–Z / Sivoromycin 500 mg Tablets

Sivoromycin 500 mg Tablets

NAFDAC Reg. No. B4-0688 · Drug

Registered with NAFDAC — registration activeAs of 5 November 2026 · synced automatically from official sources.
Product
Sivoromycin 500 mg Tablets
NAFDAC number
B4-0688
Active ingredient
Azithromycin (Azithromycin Dihydrate)
Strength
500 mg
Form
Tablet
Pack size
3 x 10's (in Alu-Alu blisters)
Manufacturer
Not listed
Applicant (holder)
Adpharm Pharmaceutical Industries Limited
Approved
26 Apr 2023
Status
Active View on NAFDAC ↗
Registration valid to
25 Apr 2028
WHO alerts
None found
Community reports
None
Times checked
0

RxVerify commentary

  • Sivoromycin 500 mg Tablets is on the NAFDAC register with an active registration (B4-0688). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.

What Sivoromycin 500 mg Tablets is used for

From the official U.S. FDA label for azithromycin (azithromycin dihydrate), the active ingredient registered with NAFDAC.

What it is used for

Azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see Dosage and Administration (2) ] Azithromycin is a macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria: • Acute bacterial exacerbations of chronic bronchitis in adults () • Acute bacterial sinusitis in adults () • Uncomplicated skin and skin structure infections in adults () • Urethritis and ce …

Possible side effects

The following clinically significant adverse reactions are described elsewhere in labeling: • Hypersensitivity [see ] • Hepatotoxicity [see ] • Infantile Hypertrophic Pyloric Stenosis (IHPS) [see ] • QT Prolongation [see Warnings and Precautions (5.4) ] • Cardiovascular Death [see ] • Clostridioides difficile- Associated Diarrhea (CDAD) [see ] • Exacerbation of Myasthenia Gravis [see ] Most common adverse reactions are diarrhea (5 to 14%), nausea (3 to 18%), abdominal pain (3 to 7%), or vomiting (2 to 7%). ( ) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. …

Do not use if

• Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug. () • Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. () 4.1 Hypersensitivity Azithromycin tablets are contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug. …

Warnings

• Serious (including fatal) allergic and skin reactions: Discontinue azithromycin if reaction occurs. () • Hepatotoxicity: Severe, and sometimes fatal, hepatotoxicity has been reported. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur. () • Infantile Hypertrophic Pyloric Stenosis (IHPS): Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs. () • Prolongation of QT interval and cases of torsades de pointes have been reported. …

Pregnancy & breastfeeding

8.1 Pregnancy Risk Summary Available data from published literature and postmarketing experience over several decades with azithromycin use in pregnant women have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data) . …

General information only — not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Sivoromycin 500 mg Tablets

Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.

3 free checks left today · no signup Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Sivoromycin 500 mg Tablets

What is in Sivoromycin 500 mg Tablets?

Sivoromycin 500 mg Tablets contains Azithromycin (Azithromycin Dihydrate) (500 mg), as tablet, according to its NAFDAC registration record.

Is Sivoromycin 500 mg Tablets registered with NAFDAC?

Yes. Sivoromycin 500 mg Tablets is listed on the NAFDAC register under registration number B4-0688, and its registration is active as of 5 November 2026.

Has Sivoromycin 500 mg Tablets been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Sivoromycin 500 mg Tablets in our automatically synced alert list.

How can I check that my pack of Sivoromycin 500 mg Tablets is genuine?

Run a free authenticity scan with the NAFDAC number B4-0688, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Sivoromycin 500 mg Tablets used for?

Azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see Dosage and Administration (2) ] Azithromycin is a macrol (Summarised from the official U.S. FDA label for azithromycin (azithromycin dihydrate). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Sivoromycin 500 mg Tablets? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.